Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BiophytisBPTSY 18 Equity-to-Asset is -1.18 as of Jun. 2025. GuruFocus rates BPTSY with a GF Score™ of 18/100. The stock has 5 warning signs investors should review. Among 1,414 Biotechnology companies, Biophytis ranks worse than 93.56% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Biophytis's Total Stockholders Equity for the quarter that ended in Jun. 2025 was $-8.98 Mil. Biophytis's Total Assets for the quarter that ended in Jun. 2025 was $7.64 Mil.
The historical rank and industry rank for Biophytis's Equity-to-Asset or its related term are showing as below:
BPTSY'
s Equity-to-Asset Range Over the Past 10 Years
Min: -1.4 Med: 0.09 Max: 0.86
Current: -1.18
During the past 13 years, the highest Equity to Asset Ratio of Biophytis was 0.86. The lowest was -1.40. And the median was 0.09.
BPTSY's Equity-to-Asset is ranked worse than 93.56% of 1414
companies
in the Biotechnology industry
Industry Median: 0.68
vs BPTSY: -1.18
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Biophytis Equity-to-Asset Related Terms
Biophytis Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Biophytis's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BPTSY vs VRTX, REGN, RVMD: Equity-to-Asset Comparison
For the Biotechnology subindustry, Biophytis's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biophytis Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Biophytis's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Biophytis's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Biophytis's Equity to Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biophytis (BPTSY) has a Equity-to-Asset of -1.18 as of Jun. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Biophytis and its competitors. According to the industry distribution chart, Biophytis ranks #1323 out of 1414 companies in the Biotechnology industry, placing it in the top 93.6%.
Is Biophytis' Equity-to-Asset too high?
Biophytis' current Equity-to-Asset is -1.18. Based on the distribution chart, Biophytis ranks #1323 out of 1414 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Biophytis has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Biophytis' Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Biophytis ranks #1323 out of 1414 companies for Equity-to-Asset. This places Biophytis in the lower half of its industry. The industry median Equity-to-Asset is 0.68. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,414 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Biophytis and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biophytis's current Equity-to-Asset is -1.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biophytis stock overvalued right now?
Biophytis (BPTSY) has a current Equity-to-Asset of -1.18. The current Equity-to-Asset is -1.18. Biophytis' overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Biophytis (BPTSY), the current Equity-to-Asset is -1.18 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Biophytis SA is a France-based clinical-stage biotechnology company engaged in the development of drug candidates for the treatment of age-related and respiratory diseases. The company focuses on therapies that target degenerative processes associated with aging and improve functional outcomes. Its drug candidate, BIO101, is an orally administered small molecule under development for neuromuscular and respiratory indications, including sarcopenia, Duchenne muscular dystrophy (DMD), and respiratory failure.
18GF Score
Get the complete analysis for BPTSY
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BPTSY has been successfully added to your 
